Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pinter

Showing results (61-70 of 135) with videos related to

Pageof 14
Sort By:
Clinical and Experimental Dermatology|August 14, 2024
Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims dataAndreas Pinter, Ahmed M Soliman, Karina C Manz, et al.
The Journal of Dermatological Treatment|May 26, 2024
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)Andreas Pinter, Kilian Eyerich, Antonio Costanzo, et al.
Journal of Clinical Medicine|February 11, 2023
Efficacy and Treatment Satisfaction of Different Systemic Therapies in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World StudySebastian Kiefer, Anke König, Viviane Gerger, et al.
Journal of the American Academy of Dermatology|June 21, 2015
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialDiamant Thaçi, Andrew Blauvelt, Kristian Reich, et al.
Advances in Therapy|July 9, 2020
Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of ChoiceSebastian Haferkamp, Mareike Alter, Dirk Debus, et al.
Advances in Therapy|April 7, 2025
Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL StudyMatthias Augustin, Esther Serra-Baldrich, Julien Seneschal, et al.
Dermatology and Therapy|April 22, 2024
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHOElisabeth Riedl, Andreas Pinter, Shirin Zaheri, et al.
Advances in Therapy|May 2, 2024
Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAmy S Paller, Andreas Pinter, Lara Wine Lee, et al.
Acta Dermato-Venereologica|September 21, 2022
Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and ResearchMarina Otten, Matthias Augustin, Christine Blome, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
Pageof 14

Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Clinical and Experimental Dermatology|August 14, 2024
Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims dataAndreas Pinter, Ahmed M Soliman, Karina C Manz, et al.
The Journal of Dermatological Treatment|May 26, 2024
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)Andreas Pinter, Kilian Eyerich, Antonio Costanzo, et al.
Journal of Clinical Medicine|February 11, 2023
Efficacy and Treatment Satisfaction of Different Systemic Therapies in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World StudySebastian Kiefer, Anke König, Viviane Gerger, et al.
Journal of the American Academy of Dermatology|June 21, 2015
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialDiamant Thaçi, Andrew Blauvelt, Kristian Reich, et al.
Advances in Therapy|July 9, 2020
Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of ChoiceSebastian Haferkamp, Mareike Alter, Dirk Debus, et al.
Advances in Therapy|April 7, 2025
Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL StudyMatthias Augustin, Esther Serra-Baldrich, Julien Seneschal, et al.
Dermatology and Therapy|April 22, 2024
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHOElisabeth Riedl, Andreas Pinter, Shirin Zaheri, et al.
Advances in Therapy|May 2, 2024
Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAmy S Paller, Andreas Pinter, Lara Wine Lee, et al.
Acta Dermato-Venereologica|September 21, 2022
Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and ResearchMarina Otten, Matthias Augustin, Christine Blome, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.
Pageof 14